UNSPSC 51332806: Carfenazine or carphenazine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CLY16Y8Z7E. European Medicines Agency schedules Carfenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06625MIG. Carfenazine generally arises in the molecular formula C24H31N3O2S.

The term CARFENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CARFENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Carfenazine or carphenazine bears US NLM identifiers UMLS ID C0771221 and NCI Concept Code C73285. SMILES: S1C2C(N(CCCN3CCN(CC3)CCO)C3C1CCCC3)CC(CC2)C(=O)CC.

UNSPSC 51332806 Carfenazine or carphenazine is a Commodity code that, based on recent state and local procurement activity, does not align with actual purchasing patterns under this designation. The three recent opportunities tagged to this code—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's RFI for direct-to-manufacturer prescription programs, and MMCAP's cooperative RFP for generic multi-source pharmaceuticals and OTC products—involve broad pharmaceutical supply, pharmacy benefit management, and generic drug distribution rather than carfenazine (a specific antipsychotic agent) procurement. The issuing bodies reflect diverse state and local structures: county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration on behalf of participating states including Oregon).

Recent activity shows geographic spread across Florida, Texas, Minnesota, and Oregon, with the most recent posting in June 2026. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline (note: deadline date appears inconsistent with posting date); Texas HHS RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's cooperative RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). The code shows limited relevance to actual carfenazine-specific procurement and warrants verification against issuing bodies' actual commodity classifications before pursuing.